glp-1 compounding crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA GLP-1 Compounding Crackdown

A higher prevalence of hypothyroidism in women with gestational diabetes mellitus (GDM) has been reported [77] and this association is also seen in postpartum thyroiditis (PPT), which is an autoimmune-mediated destructive thyroiditis in the 1st year postpartum

This actionable blueprint guides your clinician in selecting the right starting compound, anticipated dosing trajectory, and complementary protocolsall personalized to your biology before your first injection or tablet

Antidiabetic Efficacy and Outcomes GLP-1 RAs bind to GLP-1 receptors located on pancreatic -cells, increasing glucose-dependent insulin secretion and thereby improving both postprandial and overall glycemic control without significantly increasing the risk of hypoglycemia

They are not intended for human or veterinary use, consumption, diagnosis, treatment, or therapeutic application

Yen K, Wan J, Mehta HH et al (2018) Humanin prevents age-related cognitive decline in mice and is associated with improved cognitive age in humans